DaVita Aktie
WKN: 897914 / ISIN: US23918K1088
05.01.2017 23:37:00
|
DaVita Announces Joel Ackerman to be CFO
DENVER, Jan. 5, 2017 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), a leading independent medical group and leading provider of kidney care services in the United States, announced today that Joel Ackerman will join the company in February 2017 and will become its chief financial officer effective March 1, 2017.
Ackerman, 51, is chief executive officer and a board member at Champions Oncology, a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, and has been in that role since 2010. Prior to Champions Oncology, Ackerman was at Warburg Pincus from 1993 to 2008, a leading private equity firm, where he was a partner and headed up the healthcare services group.
Ackerman has served on the board of directors of Kindred Healthcare since 2008, and served on the board of directors of Coventry Health Care. He is also chair of the One Acre Fund, a not-for-profit microfinance organization serving more than 400,000 subsistence farmers in Africa.
"Joel has experience in a wide variety of health care service segments and stages of companies," said Kent Thiry, chairman and chief executive officer of DaVita. "We believe his strategic, financial, and health care industry experience will serve him well as a member of our senior leadership team."
Ackerman earned a bachelor's degree from Columbia University, where he graduated summa cum laude, and a master's degree in Physics from Harvard University.
Jim Hilger, who has served as the company's interim chief financial officer since 2015, will continue in his role as chief accounting officer, a position he has held since 2010.
About DaVita Inc.
DaVita Inc., a Fortune 500® company, is the parent company of DaVita Kidney Care and HealthCare Partners, a DaVita Medical Group. DaVita Kidney Care is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of September 30, 2016, DaVita Kidney Care operated or provided administrative services at 2,318 outpatient dialysis centers located in the United States serving approximately 186,000 patients. The company also operated 139 outpatient dialysis centers located in 11 countries outside the United States. HealthCare Partners manages and operates medical groups and affiliated physician networks in California, Nevada, New Mexico, Florida, Colorado and Washington in its pursuit to deliver excellent-quality health care in a dignified and compassionate manner. As of September 30, 2016 HealthCare Partners provided integrated care management for approximately 750,000 patients. For more information, please visit DaVita.com/about.
Contact Information
Investors:
Jim Gustafson
(310) 536-2585
jim.gustafson@davita.com
Contact Information
Media:
Skip Thurman
(303) 876-6610
skip.thurman@davita.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/davita-announces-joel-ackerman-to-be-cfo-300386762.html
SOURCE DaVita Inc.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu DaVita Inc Registered Shsmehr Nachrichten
28.04.25 |
S&P 500-Wert DaVita-Aktie: So viel Gewinn hätte ein Investment in DaVita von vor einem Jahr eingebracht (finanzen.at) | |
21.04.25 |
S&P 500-Wert DaVita-Aktie: So viel Gewinn hätte ein Investment in DaVita von vor 10 Jahren eingebracht (finanzen.at) | |
14.04.25 |
Börse New York: S&P 500 letztendlich in Grün (finanzen.at) | |
14.04.25 |
Starker Wochentag in New York: S&P 500 notiert am Nachmittag im Plus (finanzen.at) | |
14.04.25 |
NYSE-Handel: S&P 500 mittags stärker (finanzen.at) | |
14.04.25 |
S&P 500-Papier DaVita-Aktie: So viel Gewinn hätte ein Investment in DaVita von vor 5 Jahren eingefahren (finanzen.at) | |
14.04.25 |
Starker Wochentag in New York: S&P 500 zeigt sich zum Handelsstart fester (finanzen.at) | |
07.04.25 |
S&P 500-Papier DaVita-Aktie: So viel hätte eine Investition in DaVita von vor 3 Jahren abgeworfen (finanzen.at) |
Analysen zu DaVita Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
DaVita Inc Registered Shs | 122,35 | 0,25% |
|